Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448357 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
A Phase 1 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00448357 is a Phase 1 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 54 participants.
The verdict
NCT00448357, a Phase 1 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before the transplant and tacrolimus after the transplant may stop this from happening. PURPOSE: The phase I portion of this trial identified the maximum tolerated dose of busulfan after treating 40 patients on a dose-escalation scheme. We are now treating an additional 26 patients on the phase II portion of the trial at a Pharmacokinetic (PK)-directed dose of total area under curve (AUC) 6912 micrometer (uM)-min/24 hours. We transitioned to the Phase II portion of the study in October 2009.
Interventions
- DRUG fludarabine phosphate
- DRUG tacrolimus
- DRUG busulfan
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL rabbit anti-thymocyte globulin (ATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448357
The ClinicalTrials.gov registry entry for NCT00448357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT00448357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00448357 about?
NCT00448357 is a clinical study titled "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen". RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infus...
What is the current status of trial NCT00448357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2005-10. Estimated completion is 2015-11.
What interventions are being tested in trial NCT00448357?
The interventions under investigation include: fludarabine phosphate (DRUG), tacrolimus (DRUG), busulfan (DRUG), therapeutic allogeneic lymphocytes (BIOLOGICAL), rabbit anti-thymocyte globulin (ATG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00448357?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.